News | June 12, 2014

High Quality In Vitro Cell Models For Cortical Neurophysiology

untitled

AMSBIO offers an extensive range of iPSC derived neural cells including normal and Alzheimer's disease neural progenitor cells, and cerebral cortical neurons.

These neural cells are derived using integration-free, fully defined neural induction conditions. AMSBIO neural cells are capable of generating a spectrum of cortical neurons that are electrically active and have the ability to form functional synapses and circuits in vitro. Cerebral cortical neurons are implicated in numerous neurological diseases including Alzheimer's disease, autism, epilepsy and stroke. Despite strong interest in these diseases, high quality human in vitro cell models for cortical neurophysiology were unavailable until now.

AMSBIO also offer a complete suite of cell reprogramming and neural differentiation servicesto meet your neural research needs.

For cell reprogramming simply provide us with your patient/donor skin fibroblasts, blood cells or iPS cells and we will take care of the rest. After you receive the neural progenitor cells and/or functional neurons from us, AMSBIO will also provide ongoing support to facilitate adaptation of the neural cells in your experimental systems. Deriving, maintaining and differentiating iPS cells is a time consuming and labour intensive process, especially when you are dealing with multiple lines. By using AMSBIO products and professional services, you can save hundreds of hours and thousands of dollars on tissue culture. We empower scientists to focus on their research interests and not consume valuable lab time and resources in the generation of cells prior to the onset of experiments. We can efficiently differentiate the iPS cells (provided by you or generated by us) to cerebral cortical neural lineage using defined neural induction medium and substrates.

For more information, visit www.amsbio.com/Human-Neural-Stem-Cells.aspx.

SOURCE: AMS Biotechnology (AMSBIO)

Newsletter Signup
Newsletter Signup
Get the latest industry news, insights, and analysis delivered to your inbox.
Join your peers
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.